U.S. market Closed. Opens in 21 hours 3 minutes

MNMD | Mind Medicine (MindMed) Inc. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 6.10 - 6.47
52 Week Range 5.03 - 12.22
Beta 2.59
Implied Volatility 97.75%
IV Rank 16.28%
Day's Volume 1,073,927
Average Volume 1,989,866
Shares Outstanding 75,368,360
Market Cap 466,530,148
Sector Healthcare
Industry Biotechnology
IPO Date 2016-11-15
Valuation
Profitability
Growth
Health
P/E Ratio -4.02
Forward P/E Ratio -1.58
EPS -1.54
1YR Price Target 21.50
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 57
Country Canada
Website MNMD
Mind Medicine Inc is a psychedelic medicine biotech company that discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of treatments based on psychedelic substances including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC. The firm is having an approach towards developing the next generation of psychedelic inspired medicines and therapies.
MNMD's peers: ATAI, CYBN, SEEL, GHRS, AWKNF, FRLN, BPTH, VCNX, ELYM, OPT, MOLN, EWTX, ITOS, CKPT, MBIO, RVPH, FBIOP, KOD
*Chart delayed
Analyzing fundamentals for MNMD we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is passable. For more detailed analysis please see MNMD Fundamentals page.

Watching at MNMD technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on MNMD Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙